Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- VETO.PA
- Price
- 75.40
- Stock movement up
- +- (%)
- Company name
- Vetoquinol
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 892.17M
- Ent value
- 892.62M
- Price/Sales
- 1.12
- Price/Book
- 1.64
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- 22.94%
- Trailing P/E
- 11.24
- Forward P/E
- 15.27
- PEG
- -
- EPS growth
- 8.93%
- 1 year return
- -20.21%
- 3 year return
- -15.37%
- 5 year return
- 6.21%
- 10 year return
- 7.41%
Last updated: 2025-04-12
DIVIDENDS
VETO.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 11.24 |
| Price to OCF | 6.74 |
| Price to FCF | 8.44 |
| Price to EBITDA | 4.99 |
| EV to EBITDA | 5.00 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.12 |
| Price to Book | 1.64 |
| EV to Sales | 1.12 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 11.83M |
| EPS (TTM) | 6.71 |
| FCF per share (TTM) | 8.93 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 793.71M |
| Gross profit (TTM) | 326.65M |
| Operating income (TTM) | 87.75M |
| Net income (TTM) | 79.37M |
| EPS (TTM) | 6.71 |
| EPS (1y forward) | 4.94 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 41.16% |
| Operating margin (TTM) | 11.06% |
| Profit margin (TTM) | 10.00% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 162.83M |
| Net receivables | 93.15M |
| Total current assets | 383.46M |
| Goodwill | 75.94M |
| Intangible assets | 147.79M |
| Property, plant and equipment | 0.00 |
| Total assets | 706.41M |
| Accounts payable | 118.61M |
| Short/Current long term debt | 20.89M |
| Total current liabilities | 138.79M |
| Total liabilities | 163.28M |
| Shareholder's equity | 543.13M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 132.30M |
| Capital expenditures (TTM) | 26.80M |
| Free cash flow (TTM) | 105.72M |
| Dividends paid (TTM) | 24.26M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 14.61% |
| Return on Assets | 11.24% |
| Return on Invested Capital | 14.32% |
| Cash Return on Invested Capital | 19.07% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 75.20 |
| Daily high | 76.20 |
| Daily low | 74.70 |
| Daily Volume | 4K |
| All-time high | 153.00 |
| 1y analyst estimate | 96.57 |
| Beta | 0.95 |
| EPS (TTM) | 6.71 |
| Dividend per share | - |
| Ex-div date | 4 Jun 2024 |
| Next earnings date | 28 May 2025 |
Downside potential
Loading...
Downside potential data
| VETO.PA | S&P500 | |
| Current price drop from All-time high | -50.72% | -12.89% |
| Highest price drop | -58.30% | -56.47% |
| Date of highest drop | 23 Jan 2025 | 9 Mar 2009 |
| Avg drop from high | -17.98% | -11.07% |
| Avg time to new high | 28 days | 12 days |
| Max time to new high | 881 days | 1805 days |
COMPANY DETAILS
Marketcap
892.17M
Marketcap category
Small-cap
Description
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
Employees
2519
Website
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
LURE, France, March 20, 2025--Regulatory News: Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), commented: "In 2024, we delivered a solid financial year, combining growth in almost all o...
March 20, 2025
LURE, France, January 30, 2025--Regulatory News: Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), commented: "All our activities and territories are growing, with the exception of the Un...
January 30, 2025
LURE, France, January 15, 2025--Regulatory News: Vetoquinol (Paris:VETO) published its calendar of financial communication for 2025.
January 15, 2025
LURE, France, October 30, 2024--Regulatory News: At the end of September 2024, Vetoquinol (Paris:VETO) sales totaled €398 million, up +1.6% on a reported basis and +1.8% at constant exchange rates. Ov...
October 30, 2024
Dear Valued Partner,
October 16, 2024
LURE, France, September 12, 2024--Regulatory News: The Board of Directors of Vetoquinol SA (Paris:VETO) met on September 10, 2024 to review business activity and approve the financial statements for t...
September 12, 2024
LURE, France, April 29, 2024--Regulatory News: Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), commented: "The good long-term performance of our two strategic axes, Essentials and the U...
April 29, 2024
LURE, France, April 24, 2024--Regulatory News: On 24 April 2024, Vetoquinol (Paris:VETO) filed its 2023 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European...
April 24, 2024